Akero Therapeutics Q1 2023 Earnings Report

Akero Therapeutics EPS Results

• Actual EPS: -$0.55
• Consensus EPS: -$0.62
• Beat/Miss: Beat by +$0.07
• One Year Ago EPS: N/A

Akero Therapeutics Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Akero Therapeutics Announcement Details

• Quarter: Q1 2023
• Date: 5/15/2023
• Time: N/A

Akero Therapeutics (NASDAQ:AKRO), together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.